Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00458744
Other study ID # ADVL0613
Secondary ID COG-ADVL0613CDR0
Status Withdrawn
Phase Phase 1
First received April 9, 2007
Last updated August 7, 2014
Start date February 2007

Study information

Verified date August 2014
Source Children's Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I trial is studying the side effects and best dose of talotrexin in treating young patients with recurrent solid tumors or leukemia that is recurrent or does not respond to treatment.


Description:

OBJECTIVES:

Primary

- Estimate the maximum tolerated dose (MTD) and recommended phase II dose of talotrexin in younger patients with recurrent solid tumors or recurrent or refractory leukemia.

- Determine the toxicity of this drug in these patients.

Secondary

- Determine the antitumor activity of this drug in these patients.

- Assess the tolerability of the defined MTD of this drug in these patients.

OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to diagnosis (solid tumor vs leukemia).

- Stratum 1 (recurrent solid tumor): Patients receive talotrexin IV over 10 minutes on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of talotrexin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).

- Stratum 2 (recurrent or refractory leukemia): A cohort of 3-6 patients with leukemia receive treatment as in stratum 1 at the MTD determined in stratum 1. If 2 or 3 or 2 of 6 patients experience a DLT at the solid tumor MTD, accrual is stopped.

After completion of study treatment, patients are followed for 30 days.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 21 Years
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of either of the following:

- Recurrent solid tumor

- Histologically confirmed* malignancy at original diagnosis or relapse

- Measurable or evaluable disease

- Lymphoma or primary CNS tumor allowed

- Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for the past 7 days

- Recurrent or refractory leukemia

- Confirmed relapse, as defined by M3 marrow (25% blasts in bone marrow aspirate or biopsy)

- Active extramedullary disease allowed provided there is no leptomeningeal involvement NOTE: *Histological confirmation not required for intrinsic brain stem tumors

- Bone marrow metastases allowed

- Not refractory to red blood cell or platelet transfusion

- No pleural effusion or significant ascites

- No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists

- No Down syndrome

PATIENT CHARACTERISTICS:

- Karnofsky performance status (PS) 50-100% (for patients > 10 years of age) OR Lansky PS 50-100% (for patients = 10 years of age)

- Absolute neutrophil count = 1,000/mm³ (for patients with solid tumors without bone marrow involvement)

- Platelet count = 100,000/mm³ (transfusion independent)

- Hemoglobin = 8.0 g/dL

- Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min OR creatinine adjusted according to age as follows:

- No greater than 0.6 mg/dL (1 year to 23 months)

- No greater than 0.8 mg/dL (2 to 5 years)

- No greater than 1.0 mg/dL (6 to 9 years)

- No greater than 1.2 mg/dL (10 to 12 years)

- No greater than 1.4 mg/dL (13 years and over [female])

- No greater than 1.5 mg/dL (13 to 15 years [male])

- No greater than 1.7 mg/dL (16 years and over [male])

- Bilirubin = 1.5 times upper limit of normal (ULN)

- ALT = 110 U/L (ULN is 45 U/L)

- Albumin = 2 g/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No uncontrolled infection

- No known condition that, in the opinion of the investigator, would preclude study compliance

PRIOR CONCURRENT THERAPY:

- Recovered from all prior treatment-related toxicity

- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea) (for patients with solid tumors)

- At least 24 hours since prior cytoreduction therapy initiated with hydroxyurea (for patients with leukemia)

- At least 2 weeks since prior local palliative radiotherapy (small port)

- At least 6 months since prior total-body irradiation (TBI), craniospinal radiotherapy, or = 50% radiotherapy to the pelvis

- At least 6 weeks since prior substantial bone marrow radiotherapy

- At least 3 months since prior stem cell transplant or rescue without TBI

- No evidence of active graft-versus-host disease

- At least 7 days since prior growth factor therapy

- At least 7 days since prior biological therapy

- No nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates, penicillins, sulfa drugs (bactrim, septra), ciprofloxacin, tetracycline, thiazide diuretics, or probenecid within 2 days prior to, during, or within 5 days after treatment with talotrexin

- No long-acting NSAIDs (e.g., nabumetone, naproxen, oxaprozin, piroxicam) within 5 days prior to, during, or within 5 days after treatment with talotrexin

- No concurrent investigational drugs

- No concurrent anticancer agents or therapy (e.g., chemotherapy, radiotherapy, immunotherapy, or biologic therapy)

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
talotrexin

Procedure:
chemotherapy


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Children's Oncology Group National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of talotrexin Yes
Primary Toxicity Yes
Secondary Antitumor activity No
Secondary Tolerability Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1